Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Files An 8-K Other Events

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Files An 8-K Other Events
Item 8.01

As of January 15, 2020, Achillion Pharmaceuticals, Inc. (“Achillion”) and Alexion Pharmaceuticals, Inc. (“Alexion”) have each filed their respective notification and report forms to the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), with the Federal Trade Commission (“FTC”) and the Antitrust Division of the Department of Justice (“DOJ”) in connection with the proposed merger of Beagle Merger Sub, Inc., a wholly-owned subsidiary of Alexion (“Merger Sub”), with and into Achillion (the “Merger”) upon the terms and subject to the conditions set forth in the Agreement and Plan of Merger, dated as of October 15, 2019, by and among Achillion, Alexion and Merger Sub. A transaction notifiable under the HSR Act may not be completed until the expiration of a 30-calendar-day waiting period following the parties’ filing of their respective HSR Act notification forms or the early termination of that waiting period. The 30-calendar-day waiting period is scheduled to expire at 11:59 p.m. on February 14, 2020, unless the FTC or DOJ extends that period by requesting additional information from the parties.

Forward Looking Statements

This Current Report on Form 8-K contains “forward-looking statements” that do not directly or exclusively relate to historical facts. Stockholders are cautioned that any forward-looking statements are not guarantees of future performance and may involve significant risks and uncertainties, and that actual results may vary materially from those in the forward-looking statements. Factors that may contribute to such differences include, but are not limited to, the possibility that the Merger will not close when expected, if at all. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found in the risks detailed in the Company’s filings with the Securities and Exchange Commission, including in its most recent filings on Forms 10-K and 10-Q, factors and matters described or incorporated by reference in this document or in the Definitive Proxy Statement.

Story continues below

About Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body’s immune system. The Company has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD. The Company has developed a portfolio of drug candidates, including odalasvir, ACH-3422 and sovaprevir.

An ad to help with our costs